CXCL8 and rheumatoid arthritis: In the culture model of rheumatoid arthritis, treatment with lunasin reduced cytokine production by IL-6, IL-8, and matrix metalloproteinase-3 and suppressed NF-κB activation in synovial fibroblasts [46].